Benzo-fused ten-membered ring meroterpenoids: sources, chemical diversity, biological activities, and biosynthesis
Wenjie Luo , Ruishan Wang , Danièle Werck-Reichhart , Kanade Tatsumi , Changzheng Liu , Haodi Sun , Sheng Wang , Lanping Guo
Acta Materia Medica ›› 2025, Vol. 4 ›› Issue (4) : 630 -656.
Meroterpenoids, a class of hybrid natural products derived from both terpenoid and non-terpenoid biosynthetic pathways, serve as a prolific source of drug leads, because of their structural complexity and extensive bioactivities. Meroterpenoids have provided many clinical drugs or promising leads, such as mycophenolic acid (an immunosuppressant), territrem B (an acetylcholinesterase inhibitor), and pyripyropene A (a cholesterol acyltransferase-2 inhibitor). Recently, meroterpenoids featuring a benzo-fused ten-membered ring skeleton have attracted considerable attention for their unique scaffolds and diverse post-modifications. Bioactivity evaluations have revealed that nearly half of these compounds (32 of 66) exhibit cytotoxicity with half-maximal inhibitory concentrations below 10 μM, and therefore have great potential as drug development candidates, particularly in cancer therapy. However, a systematic summary of this subclass remains lacking. Herein, we summarize benzo-fused ten-membered ring meroterpenoids reported between 1980 and 2024, including their sources, structural diversity, bioactivities, and biosynthetic pathways, to provide comprehensive insights to guide further studies on meroterpenoids.
Benzo-fused ten-membered ring meroterpenoids / Structural diversity / Cytotoxic activity / Biosynthetic pathway / Natural product drug leads
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
|
| [28] |
|
| [29] |
|
| [30] |
|
| [31] |
|
| [32] |
|
| [33] |
|
| [34] |
|
| [35] |
|
| [36] |
|
| [37] |
|
| [38] |
|
| [39] |
|
| [40] |
|
| [41] |
|
| [42] |
|
| [43] |
|
| [44] |
|
| [45] |
|
| [46] |
|
| [47] |
|
| [48] |
|
| [49] |
|
| [50] |
|
| [51] |
|
| [52] |
|
| [53] |
|
| [54] |
|
| [55] |
|
| [56] |
|
| [57] |
|
| [58] |
|
/
| 〈 |
|
〉 |